E

Epic Medical Research | DeSoto, TX

Research site

(Unclaimed)

Location

935 York Drive, DeSoto, Texas, United States of America

Site insights

Top conditions

Top treatments

Lunsekimig

JATENZO®

SAR443765

HTD1801

CIN-102

Sugar

deudomperidone

Parent organization

This site is a part of Epic Medical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 8 total trials

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men...

Active, not recruiting

Hypogonadism

Drug: Jatenzo

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes (ONWARDS 11)

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investi...

Not yet enrolling

Diabetes Mellitus, Type 1

Drug: Insulin glargine

Drug: Insulin icodec

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopa...

Enrolling

Idiopathic Gastroparesis

Drug: Placebo

Drug: CIN-102 Dose 15mg

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes (ReCET)

This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabet...

Enrolling

Diabetes

Type2diabetes

Device: ReCET Treatment

Device: Sham Procedure

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (AIRLYMPUS)

This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.The purpose of this study is...

Enrolling

Asthma

Drug: Short-Acting Beta Agonists (SABA)

Drug: Fluticasone/salmeterol